CMV reactivation remains the main cause of viral complications after allogeneic hematopoietic stem cell transplantation (aHSCT).
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In particular, CMV with gene mutations against antiviral drugs can lead to a high mortality rate. 2 Nichols et al. 3 reported that increased viral load happened in 39% of patients because of the latent immunosuppression after preemptive therapy. Moreover, PBSC transplantation (PBSCT) showed a faster immune recovery compared with bone marrow transplantation 4, 5 and could reduce the risk of persistent CMV antigenemia and disease. 6 It appears that drug resistance should be suspected in patients who had viral load increases for more than 2 weeks of antiviral therapy and the category and degree of host immunosuppression have great impact on drug resistance. Thus, a retrospective study was analyzed to explore the clinical risk factors and outcome for CMV reactivation and CMV clinically refractory to antiviral chemotherapy.
A total of 685 patients underwent aHSCT with a myeloablative conditioning regimen in the First Affiliated Hospital of Soochow University between January 2011 and 31 July 2014. The median time of follow-up was 16.7 months (range 1-46) through 30 April 2015. The characteristics of the patients are summarized in Table 1 . GvHD prophylaxis consisted of cyclosporine and short term methotrexate, whereas patients with mismatched or unrelated donors also received mycophenolate mofetil as the part of GvHD prophylaxis. Meanwhile, 441 of all patients received antithymocyte globulin (ATG) as a component of GvHD prophylaxis. Degree and the treatment of acute GvHD (aGvHD) were executed according to the established categories and protocols. 7, 8 All patients received regularly CMV reactivation assessment, which was implemented by quantitative real-time PCR (qPCR) using the Diagnostic kit for Quantification of Human Cytomegalovirus DNA (DaAn Gene co. Ltd of Sun Yat-sen University in Guangzhou, China), or pp65 Antigenemia assay with CMV-pp65 kit indirect immunofluorescence (Tianjin, Super Biotechnology Development Co. Ltd, China). The qPCR tests of all donors and recipients were negative (o 100 copies/mL) pre-transplantation. A prophylactic therapy on CMV reactivation was performed as follow: ganciclovir (GCV, 10 mg/kg day) from day − 9 to − 2 and acyclovir (1500 mg/m 2 day) from day − 1 until one year post transplantation. CMV reactivation was defined as a positive result in either qPCR (two consecutive values ⩾ 100 copies/mL in blood plasma sample) or pp65 antigenemia (⩾1 Ag-positive cell per 2.0 × 10 5 leukocytes). CMV disease was defined as the commonly accepted categories. 2 Clinically refractory CMV reactivation (cRCR) was defined as a persistent pp65 positive or an unchanged/increasing copy number in qPCR with 14 days of preemptive treatment but no gene mutations were performed. 9 Patients with cRCR were re-induced with antiviral chemotherapy (foscarnet, GCV, both or cidofovir), along with reduction of immunosuppression therapy if possible. The preemptive antiviral therapy was initiated when CMV reactivated. Induction therapy was kept for 14 days at least. If viral load of CMV qPCR was decreased or pp65 turned negative during follow-up, a maintenance dose was continued until two sequential CMV detection results turned negative. When GCV intolerance occurred, foscarnet (180 mg/kg day) was used as a substitution for 2 weeks treatment in patients with severe cytopenia. Foscarnet doses were adjusted according to continuous monitoring of CMV detection results and patients' renal function.
The active disease phase pre-transplantation contained the following: relapse, advanced disease or CML under acceleration period or blast crisis, and patients with myelodysplastic syndrome RAEB (MDS-RAEB n = 48). The chronic phase of CML and other benign diseases were not classified as a state of advanced disease. Abbreviations: AA = aplastic anemia; ATG = antithymocyte globulin; BM = bone marrow; Bu = busulfan; CB = cord blood; Cy = cyclophosphamide; MDS = myelodysplastic syndrome; MPD = myeloproliferative diseases; PNH = paroxysmal nocturnal hemoglobinuria.
Non-relapse mortality (NRM) was defined as death from all causes except for relapse. Overall survival (OS) was defined as the time from aHSCT to death or to the last observation. χ 2 test or exact test was used to compare the categorical variables with a 5% significance level. Univariate analysis and multivariate logistic regression models were used to estimate odds ratio (OR) and the corresponding 95% confidence intervals (CI) as a measure of association between CMV reactivation or cRCR and the categorical variables. Factors significantly below the 5% level in univariate analysis were included in the multivariate logistic regression. Kaplan-Meier method and the log-rank test were used in analyzing the cumulative incidence of CMV disease, OS and NRM.
Retrospectively, 282 of 685 (41.2%) patients developed CMV reactivation. The incidence of CMV reactivation was 49.8% in patients with related HLA-haploidentical donors (HID) or matched unrelated donors (MUD) compared with 24.9% in patients with HLA-identical sibling donors (Po 0.001), 44.9% in age ⩽ 31 years versus 37.4% in age 431 years (P = 0.047), 54.1% in the stem cell source from cord blood (CB) or bone marrow (BM) versus 39.0% from PB or PB plus BM (P = 0.005), 52.9% in aGvHD grade ⩾ 2 versus 34.1% in grade o 2 (P o0.001), 47.8% in ATG versus 29.1% in non-ATG (P o 0.001) and 42.8% in recipients with positive CMV serostatus versus 15.0% with negative CMV serostatus (P = 0.001). Different dose of methylprednisolone (MP) for aGvHD treatment also affected CMV reactivation: 54.2% (MP ⩾ 2 mg/kg day) versus 46.4% (MP 1-2 mg/kg day) versus 33.0% (MP o1 mg/kg day) (P o 0.001). In the multivariate analyses, HID-or MUD-HSCT (P o 0.001; OR, 3.41; 95% CI, 1.72-6.78), a positive CMV serostatus of recipients (P = 0.001; OR, 4.71; 95% CI, 1.90-11.65), the occurrence of aGvHD ⩾ grade 2 (P = 0.045; OR, 1.68; 95% CI, 1.01-2.79) have increased risk of CMV reactivation. Moreover, patients who were given PB as the stem cell source had a greatly reduced probability of CMV reactivation (P = 0.005; OR, 0.51; 95% CI, 0.32-0.82).
Eighty-four of 282 (29.8%) patients developed cRCR. Owing to different standard, this rate of suspected resistance was 410.7% reported by Hantz et al. 2 The association of cRCR with clinical variables is showed in Table 2 . Univariate analysis revealed that cRCR occurred frequently in HID-or MUD-HSCT (P = 0.035), patients who with BM or CB as stem cell source (P = 0.038), or patients who developed aGvHD grade ⩾ 2 (P = 0.027). Although not statistically significant, the prevalence of cRCR tended to be higher in patients with TBI-containing regimens (46.2% versus 28.1%) (P = 0.055; OR, 2.19; 95% CI, 0.97-4.96). Meanwhile, compared with MP o 1 mg/kg day for aGvHD treatment, the prevalence of cRCR tended to be higher in patients with MP 1-2 mg/kg day (P = 0.084; OR, 1.76; 95% CI, 0.93-3.35) and ⩾ 2 mg/kg day (P o 0.001; OR, 3.20; 95% CI, 1.68-6.07). The multivariate analysis confirmed that HID-or MUD-HSCT (P = 0.019; OR, 2.49; 95% CI, 1.16-5.35), without use of PB as stem cell source (P = 0.011; OR, 0.41; 95% CI, 0.21-0.82), and TBI-containing regimens (P = 0.048; OR, 2.49; 95% CI, 1.01-6.13) were associated with increased risk of developing cRCR. Moreover, the prevalence of cRCR was nearly three and six times higher among patients who received MP 1-2 mg/kg day (P = 0.024; OR, 2.74; 95% CI, 1.15-6.56) and ⩾ 2 mg/kg day (P = 0.001; OR, 6.03; 95% CI, 2.12-17.20).
At the end of this follow-up period, 37 of 282 (13.5%) patients with CMV reactivation progressed to CMV diseases. The incidence of CMV disease was 26.2% (22/84) in patients with cRCR, compared with 7.6% (15/198) of those without cRCR (P o0.001). Meanwhile, a worse OS (53.6% versus 67.2%, P = 0.004) and a higher NRM (31.0% versus 22.2%, P = 0.027) occurred between patients with and without cRCR. Seventy-nine of 84 cases developed early cRCR during 100 days post transplantation, whereas 5 cases developed late cRCR. CMV disease of these two Table 2 . Univariate and multivariate analysis of clinically refractory CMV reactivation after aHSCT
Patient characteristics
Risk factor cRCR N (%) P-value a OR (95% CI) Letter to the Editor groups was 24.1% (19/79) and 60.0% (3/5) (P = 0.185). In addition, 5 of 79 (6.3%) patients with early RCR used PP65 as CMV detection only, whereas 1 of 5 cases (20%) progressed to CMV disease. When considering other 74 (93.7%) cases who also adopted qPCR detection, initial copy number of CMV-DNA was chosen as baseline. Forty-two of them had at least a double increase from baseline after initial 2 weeks of antiviral therapy, whereas other 32 cases had less than double increase from baseline. The incidence of CMV disease of these two subgroups was 35.7% (15/42) versus 9.4% (3/32) (P = 0.011). Moreover, the NRM and OS of them were 33.3% versus 12.5% (P = 0.031) and 50.0% versus 71.9% (P = 0.048).
In conclusion, our data revealed that host factors such as mismatch aHSCT, using stem cell sources other than PB and the use of high-dose systemic corticosteroids increased CMV reactivation and cRCR. CMV reactivation clinically refractory to antiviral therapy does affect the outcome of transplant recipients. This finding was consistent with previous studies. 3, 4, 5, 6, 10, 11 Although the twofold increase above the baseline of CMV-DNA showed a worse outcome, it needs further research to confirm whether this end point can be used as an independent prognostic factor. Hence, the type and degree of immunosuppression after aHSCT appear to have a great impact on the risk of CMV reactivation and cRCR. When CMV reactivation clinically refractory to antiviral therapy occurred, genotypic assays for mutations should be performed if possible.
